amining predictors of medication class prescribed. RESULTS: There were 4,916 individuals in the study (1,788 in DA cohort, and 2,482 in LD). Results of the logistic regression revealed that older patients were significantly less likely to receive DA (ORϭ0.977; 95% CI 0.966-0.988) or a ), compared to LD. Compared to LD cohort, patients who receive a MAO-B were significantly less likely to be diagnosed with pre-period depression (ORϭ0.540; 95% CI 0.310-0.940) and patients who received a MAO-B or DA were significantly less likely to be diagnosed with psychoses (MAO-B -ORϭ0.220; 95% CI 0.105-0.459: DA -ORϭ0.732; 95% CI 0.542-0.989). Furthermore, results revealed that patients diagnosed by a neurologist were significantly more likely to receive a DA (ORϭ1.651; 95% CI 1.353-2.014) or a ), compared to LD. Region of residence and health plan membership were also found to predict initial medication class. CONCLUSIONS: These analyses indicate that patient characteristics, health status, diagnosing physician and access disparities all impact initial therapeutic class of medication prescribed for patients with PD.
OBJECTIVES:
Multiple Sclerosis (MS) was the only category that experienced triple digit growth in sales, leading to doubling of their sales from $3.4 billion in 2007 to $7 billion in 2011. This has led to change in payer coverage and utilization of branded MS products. This study was undertaken to understand current trends in sales, access and utilization management for MS products in the United States. METHODS: Sales data for MS branded products was analyzed using IMS Health 2007-2011 data. Access and utilization management trends were analyzed using preferred drug list and coverage policies of top US health plans. Primary discussions were conducted with pharmacy and medical directors to understand new trends in coverage of MS products. RESULTS: More than half (approximately 59%) of the branded MS products are covered by health plans as non-preferred products or at Tier 3/4 . Significant majority (84%) of these products were covered with prior authorization or pre-certification criteria. Quantity limits were used by 34% of the plans. Use of step therapy or progression prescription is not currently common and was found in only 5% of the plans. In this sample (nϭ37), only one plan (Ͻ 5%) had formulary exclusion for an MS product. Payer designated specialty pharmacies are increasingly being used by various health plans. Compared to 2007, payer coverage of MS products shows significant increase in use of PA (40% in 2007 PA (40% in versus 84% in 2012 . Payers express high concern for rapidly growing MS category and report use of more utilization management approaches to control spending. CONCLUSIONS: MS products are facing more aggressive utilization management. Patient access for new MS therapies could be limited due to non-preferred status, high co-pay or strict PA criteria. documented by a neurologist or psychiatrist or at least one disease modifying drug (DMD) prescription (interferon beta-1(a/b), glatirameracetat, or natalizumab). All cases of outpatient medical services with an MS diagnosis were considered. Analysis of MS-associated drug therapy included DMD, drugs used for symptomatic relief and systemic corticosteroids for relapse therapy. Persistence (duration of continuous prescription) and medication possession ratio (MPR; percentage of days covered by medication) were calculated for DMD. RESULTS: The annual number of MS patients ranged from nϭ12.800 (2005) 
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PND74 HOW HAVE MANUFACTURERS OVERTURNED NEGATIVE REIMBURSEMENT DECISIONS? A CASE STUDY USING NATALIZUMAB FOR MULTIPLE SCLEROSIS
Philips Z, Guarnieri C, Brown A Abacus International, Manchester, UK OBJECTIVES: To identify and explore how reimbursement decisions for natalizumab, a treatment for multiple sclerosis (MS), were overturned from an initial rejection to a recommendation. METHODS: This analysis was conducted in conjuntion with a wider review of the global reimbursement landscape for MS therapies. We reviewed reimbursement decisions or recommendations from global payer decision-making agencies, including any decisions where an initial rejection was overturned. We reviewed the agency rationale for both the original and subsequent decisions, and how the manufacturer influenced the decision reversal. RESULTS: Since 2006, 17 payer decisions for natalizumab were identified (six recommendations, eight restricted recommendations and three rejections). The three rejected decisions were later overturned by the manufacturer submitting further evidence. To PBAC this involved re-defining the indirect comparison to consider the heterogeneity in the trials included. To SMC and CADTH post-hoc analysis was submitted for the specific subgroup of rapidly evolving severe relapsing remitting MS. For CADTH a 15% price discount was agreed in addition. Across all agencies clinical need was an important factor. CONCLUSIONS: By emphasising unmet needs, submitting further evidence in defined subgroups and ensuring indirect comparisons are methodologically sound, it has been possible to overturn initial negative decisions by payer agencies to restricted recommendations in define subgroup. Identification of the optimum treatable population has proved pivotal in the reversal of fortune. 
RESPIRATORY-RELATED DISORDERS -Clinical Outcomes Studies
PRS1 THE USE OF MONTELUKAST AND NEUROPSYCHIATRIC DISTURBANCES AMONG PEDIATRIC ASTHMATICS: A NESTED CASE-CONTROL STUDY
OBJECTIVES:
There is conflicting evidence in published literature regarding the association between montelukast and neuropsychiatric disturbances. We sought to determine if the use of montelukast was associated with neuropsychiatric disturbances in children with Asthma. METHODS: A 10% sample of the LifeLink health plan claims data was used to identify subjects less than 18 years of age with a primary diagnosis of asthma between Jan 1, 1998 and Dec 31, 2009. Multiple case definitions for neuropsychiatric disturbances were formulated ranging from narrow to broad measures based on the diagnoses of neuropsychiatric related disorders or use of a psychotropic medication. We used a nested case control design and each case was matched to 3 controls on age, gender and geographic region and controls were assigned an index date based on the matched case. Exposure to montelukast was measured as any exposure during the year, recency of exposure, cumulative duration of exposure and cumulative dose of exposure during the 30 days and 365 days prior to the outcome. Conditional logistic regression was used to estimate the unadjusted and the adjusted odds ratios after controlling for confounders. RESULTS: Using the broadest definition for neuropsychiatric disturbances, 1,920 cases and 5,760 matching controls were identified. Cases were more likely to be diagnosed with epilepsy, diabetes, cancer and hypothyroidism, and were more likely to use inhaled corticosteroids, long-acting beta2-agonists, systemic corticosteroids and metoclopramide. Subjects exposed to montelukast during the year had an unadjusted OR of 1.085 ) and an adjusted OR of 1.032 (CI 0.909 -1.172) for experiencing a neuropsychiatric disturbance. None of the other montelukast exposure measures showed a positive association except a cumulative dose of exposure between 351mg and 900mg (ORϭ1.308; CI: 1.082 -1.581). CONCLUSIONS: Preliminary results do not suggest a consistent positive association between montelukast and neuropsychiatric disturbances. Nycomed Korea Co., Ltd., Seoul, South Korea, 2 Hallym University Sacred Heart Hospital, Gyeonggi-do, Dongan-gu, South Korea OBJECTIVES: COPD is an important cause of morbidity and mortality. Statistics Korea presented in 2009 the mortality of COPD was 9.4 per one hundred thousand marking the disease as one of the 10 major death causes in Korea. This study was performed to investigate epidemiologic data especially incidence and risk factors associated with COPD exacerbations in Korea. METHODS: A retrospective observational study was carried out on 1,112 COPD patients from 47 medical centers throughout Korea. The data collection was performed at enrollment and a past year from the enrollment. The COPD patients were defined by GOLD criteria 2010. Also we investigated demographic characteristics, COPD exacerbation, Lung function Test, Comorbidity, COPD assessment test (CAT), and COPD medication. RESULTS: Among 1,112 patients, more than half of the respondents were more than 70 years old, 91% (nϭ1,011) were male, mean BMI was 22.2 (SD 3.3) kg/m 2 , mean COPD duration was 5.8 years, and 55.5% (nϭ616) were classified as chronic bronchitis. The occurrence of exacerbation was 35.4% (nϭ394), the mean frequency of exacerbation in past year was 0.67 (SD1.28), and decrease of FEV1/FVC results align with GOLD stage was statistically significant (pϽ0.0001). The most frequently reported comorbidities were hypertension (36.0%, nϭ400) and bronchial asthma (16.6%, nϭ185). Mean CAT sum score was 16.8 (SD 8.3). The most frequently used COPD medication was long-acting muscarinic antagonist (47.9%). Multivariate logistic regression results show the effect on exacerbation in the subjects who had only pulmonary emphysema was 0.7 times than the subjects who had only chronic bronchitis (95%CI [0.49-0.96], p-valueϭ0.001), and subjects with history of pneumonia were 11.1 times higher than in the subjects without history of pneumonia (95% CI [6.89-17.87], p-valueϽ0.0001). CONCLUSIONS: Our results suggested that the A559 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 2 7 7 -A 5 7 5
